Kynurenine and Pteridines in Changes of Membrane Fluidity

  • V. Rudzite
  • E. Jurika
  • D. Fuchs
  • G. Baier-Bitterlich
  • H. Wachter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 398)


Examination of blood serum lipid and kynurenine content in patients with ischemic heart disease and patients with essential hypertension showed that the elevated whole cholesterol and decreased HDL-cholesterol content were not dependent on kynurenine accumulation in blood. The difference was found out in triglycerol and phospholipid amount. Kynurenine accumulation was followed by an increase of triglycerol and a decrease of phospholipid, especially lecitin amount as well as an increased saturated and decreased unsaturated fatty acid content of phospholipids (Rudzite et al.,1988, 1994). The same changes of lipids were also found in white rats with experimentally induced kynurenine accumulation in blood serum (Rudzite and Jurika, 1991). Moreover, kynurenine addition to incubation medium for phospholipid biosynthesis in vitro was followed by an increase of palmitic and oleic acid, a decrease of linoleic and arachidonic acid incorporation into phospholipids. Further studies showed, that similar deviation in fatty acid incorporation into phospholipids was seen after neopterin addition to incubation medium for phospholipid biosynthesis in vitro. The difference was only in oleic acid incorporation:neopterin decreased, while L-kynurenine increased the oleic acid incorporation into phospholipids (Rudzite et al., 1993,1994).


Arachidonic Acid Incubation Medium Fatty Acid Content Membrane Fluidity Cholesterol Content 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cloete F., de Waal J.M., Badenhorst P.W., Kelderman M. 1993,Abnormal fatty acid — composition of plasma and platelets in patients with acute myocardial infarction. In:Abstracts of 1st International Congress “Fatty Acids and Lipids from Cell Biology to Human Disease. Lugano, Switzerland, p. 109.Google Scholar
  2. Ferber E., Kroner E., Schmidt B., Ficher H., Peskar B,A., Anders C. 1980, Dynamics of membrane fatty acids during lymphocyte stimulation by mitogens. In:Membrane Fluidity.Biophysical Techniques and Cellular Regulation. M. Kates and A. Kuksis Eds. The Humana Press Inc. Clifton, New Jersey, p. 239 –263.Google Scholar
  3. Folch J., Lees M., Stanley G.H. 1957, A simple method for isolation and purification of total lipids from animal tissues, J. Biol Chem.226:495.Google Scholar
  4. Fuchs D., Samsonov M., Titz G.P, Reibnegger G., Belenkov J.N., Nassonov E.L., Wachter H. 1993, Stimulated cellular immune systems in patients with congestive heart failure, Eur. J. Clin. Biochemistry, 31:111Google Scholar
  5. Homolka J., 1964, Bestimmung des anorganischen Phosphors nach Urbach-Raabe (modifiziert). In:Chemische Diagnostik im Kindersalter mit Bevorzugung der mikrometrischen Blutanalysen. WEB, Verlag Volk und Gesundheit, Berlin, p. 354–355.Google Scholar
  6. Kates M. 1978, Technique of Lipidology. Mir, Moscow, p. 201–203. (Russ.)Google Scholar
  7. Montilla C., Muniz O., Villar J., Ruiz-Gutierrez V., Stiefer P., Serreras J.L. 1993, Erythrocyte membrane cholesterol and phospholipids composition in hypertensives vs normotensives. In:Abstracts of 1st International Congress“ Fatty acids and Lipids from Cell Biology to Human Disease” Lugano, Switzerland, p. 116.Google Scholar
  8. Muniz O., Montilla C., Villar J., Ruiz-Guitierrez V., Stiefer P., Serreras J.L., 1993, Erythrocute membrane fatty acids composition in hypertensives vs normotensives. Abstracts of 1st International Congress “Fatty Acids and Lipids From Cell Biology to Human Disease” Lugano, Switzerland, p.l 16.Google Scholar
  9. Nilsson S., 1970, Synthesis and Secretion of biliary phospholipids by man, Acta Chirurg. Scand. Suppl.405:1Google Scholar
  10. Olivieri O.,Stanzial A.M.,Girelli D.,TrevisanM.T.,Guarini P., Terzi M., CafFi S., Fontana F., Casaril M., Ferrari S., Corrocher R., 1993, Selenium, status fatty acids, antioksidant vitamins and aging. The nove study. In:Abstract of 1st International Congress’Tatty Acids and Lipids from Cell Biology to Human Disease “Lugano, Switzerland, p. 136.Google Scholar
  11. Ostro M.J., Bessinger B., Summers J., Dray S., 1980, Effect of membrane lipid composition on mobility of lymphocyte surface immunoglobulins. In:Membrane Fluidity. Biochemical Techniques and Cellular Regulation. M. Kates and A Kuksis Eds.The Humana Press Inc.Clifton, New Jersey, p. 105 – 117.Google Scholar
  12. Predtetchenski V.J., Borovskaja V.M., Margolina L.T. Handbook of Clinical and Laboratory Investigation, Medgiz, Moscow. (Russ.)Google Scholar
  13. Reibnegger G., Huber L.A., Jtirgens G., Schonitzer D., Werner E.R., Wachter H., Wick G., Traili K. N., 1988, Approach to define “normal aging” in man. Immune function, serum lipids, lipoproteins and neopterin levels. Mech. Aging Developm., 46:67.CrossRefGoogle Scholar
  14. Rudzite V., Jurika E.,Arajs J.,Andrejev N., 1987,The relationship between kynurenine and arterial blood pressure. In:Progress in Tryptophan and Serotonin Research 1986. Bender D.A., Joseph M.H., Kochen W., Steinhart H. Eds. Walter de Gruyter & Co, Berlin — New York, p. 127 – 130.Google Scholar
  15. Rudzite V., Jirgensons J., Jurika E., Sileniece G., Zirne R., Jirgensone S., 1988, Besonderheiten der Nikotin- saurebildung bei koronarer Herzkrankheit unter Beriicksichtigung von Herzrhythmusstorungen. Z gesamte inn. Med., 43:60Google Scholar
  16. Rudzite V., Jurika E., 1991, Kynurenine and Lipid Metabolism. Advances in Expe rimental Medicine and Biology. 294:463.Google Scholar
  17. Rudzite V., Sileniece G., Liepina D., Dalmane A., 1991, Impairment of kynurenine metabolism in cardiovascular disease. Advances in Experimental Medicine and Biology, 294:663.Google Scholar
  18. Rudzite V Skards J.I., Fuchs D., Reibnegger G., Wachter H., 1992, Serum kynurenine and neopterin concentrations inpatients with cardiomyopathy Immunol. Lett. 32:125.CrossRefGoogle Scholar
  19. Rudzite V., Jurika E., Reibnegger G., Weiss G., Wachter H., 1993, Influence of Kynurenine, Neopterin, Noradrenaline and Pyridoxal - 5 - Phosphate on Cholesterol Content and Phospholipid Biosynthesis in vitro. Pteridines, 4:126Google Scholar
  20. Rudzite V., Jurika E., Fuchs D., Reibnegger G., Wachter H., 1994, The influence of kynurenine, neopterin and pyridoxal -5-phosphate /P-5-P/ on cholesterol content and phospholipid biosynthesis in vitro. In:L-Tryptophan Current Prospects in Medicine and Drug Safety. Kochen W. and Steinhart H. Eds. Walter de Gruyter, Berlin - New York, 165 – 170.Google Scholar
  21. RudziteV., Sileniece G.,Jirgensons J., Dalmane A., Zirne R., Jurika E., Skards J.I., 1994, The significance of increased kynurenine levels in blood to the development of cardiovascular pathology. Acta Medica Baltica, 1:4.Google Scholar
  22. Samsonov M.,Fuchs D.,Reibnegger G.,Belenkov J.N.,Nassonov E.L.,Wachter H., 1992, Patterns of serological markers for cellular immune activation in patients with dilated cardiomyopathy and chronic myocarditis. Clin. Chem., 38:678.Google Scholar
  23. Tatzber F.,Rabl H.,Koriska K.,Erhart U., Puhl H.,Waeg G., Krebs A., Esterbauer H., 1991, Elevated serum neopterin levels in atherosclerosis.Atherosclerosis89:203.Google Scholar
  24. Weber E., 1957, Grundri der biologischen Statistik fur Naturwissenschaftler, Landwirte und Mediziner. Gustav Fischer Verlag, Jena.Google Scholar
  25. Weiss G.,Fuchs D.,Hausen A.,Reibnegger G., Werner E.R., Werner-Felmayer G., Semenitz E Dierich M.P, Wachter H., 1993, Neopterin modulates toxicity mediated by reactive oxygen and chloride species. FEBS Lett., 89.Google Scholar

Copyright information

© Plenum Press, New York 1996

Authors and Affiliations

  • V. Rudzite
    • 1
  • E. Jurika
    • 1
  • D. Fuchs
    • 2
  • G. Baier-Bitterlich
    • 2
  • H. Wachter
    • 2
  1. 1.Laboratory of Biochemistry LatviaInstitute of CardiologyRigaLatvia
  2. 2.Institute of Medical Chemistry and BiochemistryUniversity of InnsbruckInnsbruckAustria

Personalised recommendations